Antengene
Edit

Antengene

http://www.antengene.com/
Last activity: 22.03.2024
Categories: InterestLivingManagementManufacturingProductDevelopmentDrugExchangeHealthTech
Antengene is a global biopharmaceutical company focused on innovative oncology therapies. Our vision is to treat patients beyond borders and transform their lives by discovering, developing, commercializing and manufacturing the most advanced therapies in the world. On November 20, 2020, we were successfully listed in the Hong Kong Stock Exchange (SEHK:6996.HK), and became one of the Hong Kong-listed biopharmaceutical companies with the shortest listing process. Since entering operation in April 2017, we have built a highly differentiated and synergistic pipeline of 12 drug assets, including six clinical stage assets which we in-licensed from Karyopharm, Celgene and AstraZeneca; and six preclinical assets that are largely inhouse discovered. We have planned and already initiated 28 clinical trials in Korea, Australia, and China, including 5 registrational clinical trials ongoing in China. Our core product, ATG-010 (selinexor, XPO1 inhibitor), is the first and only approved selective inhibitor of nuclear export, which has already been launched in the U.S. and Israel for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Antengene obtained exclusive rights for the development and commercialization of ATG-010 (selinexor) in 17 APAC countries and regions and submitted NDAs for ATG-010 (selinexor) in five APAC markets. Taking hematologic malignancy as one of our core therapeutic areas, we have built a management team with a global background and strong track records in the clinical development and commercialization of therapies, including REVLIMID®, a multi-million dollar oncology product, and POMALYST®, one of the best-selling oncology products worldwide.
Followers
3.01K
Mentions
108
Location: China, Shanghai
Employees: 51-200
Total raised: $238M
Founded date: 2017

Investors 2

Funding Rounds 3

DateSeriesAmountInvestors
20.07.2020Series C$97MQiming Ven...
16.01.2019Series B$120M-
16.08.2017Series A$21M-

Mentions in press and media 108

DateTitleDescriptionSource
22.03.2024Antengene Announces Full Year 2023 Financial Results, Highli...Promising clinical activities and efficacies during dose escalations for four lead global rights pro...en.prnasia...
20.03.2024Antengene Initiates Phase II Dose Expansion Study of Claudin...SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengen...en.prnasia...
20.03.2024Antennova Completes First Dosing Cohort for Anti-CD24 mAb, A...ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncolog...en.prnasia...
20.03.2024Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispeci...SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengen...en.prnasia...
06.03.2024Antengene to Present Four Preclinical Abstracts at AACR 2024...The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as wel...en.prnasia...
14.12.2023Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023...SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene...en.prnasia...
06.12.2023Antengene Announces XPOVIO® Regulatory Approval in Macau for...XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. XPOVIO® has...en.prnasia...
17.11.2023Antengene Presents Encouraging Clinical Data from Four Pipel...Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibo...en.prnasia...
08.11.2023Antengene to Host 2023 R&D Day and Discuss Key Data with...During the event, Antengene will review promising data of its R&D pipeline, including ATG-031 (a...en.prnasia...
01.11.2023Antengene Presents Results from Five Investigational Program...SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&...en.prnasia...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In